Literature DB >> 16107723

Multiple fates of L1 retrotransposition intermediates in cultured human cells.

Nicolas Gilbert1, Sheila Lutz, Tammy A Morrish, John V Moran.   

Abstract

LINE-1 (L1) retrotransposons comprise approximately 17% of human DNA, yet little is known about L1 integration. Here, we characterized 100 retrotransposition events in HeLa cells and show that distinct DNA repair pathways can resolve L1 cDNA retrotransposition intermediates. L1 cDNA resolution can lead to various forms of genetic instability including the generation of chimeric L1s, intrachromosomal deletions, intrachromosomal duplications, and intra-L1 rearrangements as well as a possible interchromosomal translocation. The L1 retrotransposition machinery also can mobilize U6 snRNA to new genomic locations, increasing the repertoire of noncoding RNAs that are mobilized by L1s. Finally, we have determined that the L1 reverse transcriptase can faithfully replicate its own transcript and has a base misincorporation error rate of approximately 1/7,000 bases. These data indicate that L1 retrotransposition in transformed human cells can lead to a variety of genomic rearrangements and suggest that host processes act to restrict L1 integration in cultured human cells. Indeed, the initial steps in L1 retrotransposition may define a host/parasite battleground that serves to limit the number of active L1s in the genome.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16107723      PMCID: PMC1190285          DOI: 10.1128/MCB.25.17.7780-7795.2005

Source DB:  PubMed          Journal:  Mol Cell Biol        ISSN: 0270-7306            Impact factor:   4.272


  75 in total

1.  BLAT--the BLAST-like alignment tool.

Authors:  W James Kent
Journal:  Genome Res       Date:  2002-04       Impact factor: 9.043

2.  A transient assay reveals that cultured human cells can accommodate multiple LINE-1 retrotransposition events.

Authors:  W Wei; T A Morrish; R S Alisch; J V Moran
Journal:  Anal Biochem       Date:  2000-09-10       Impact factor: 3.365

Review 3.  The unusual phylogenetic distribution of retrotransposons: a hypothesis.

Authors:  Jef D Boeke
Journal:  Genome Res       Date:  2003-09       Impact factor: 9.043

4.  Genomic deletions created upon LINE-1 retrotransposition.

Authors:  Nicolas Gilbert; Sheila Lutz-Prigge; John V Moran
Journal:  Cell       Date:  2002-08-09       Impact factor: 41.582

5.  Human L1 retrotransposon encodes a conserved endonuclease required for retrotransposition.

Authors:  Q Feng; J V Moran; H H Kazazian; J D Boeke
Journal:  Cell       Date:  1996-11-29       Impact factor: 41.582

6.  Human L1 element target-primed reverse transcription in vitro.

Authors:  Gregory J Cost; Qinghua Feng; Alain Jacquier; Jef D Boeke
Journal:  EMBO J       Date:  2002-11-01       Impact factor: 11.598

7.  The disabled 1 gene is disrupted by a replacement with L1 fragment in yotari mice.

Authors:  T Kojima; K Nakajima; K Mikoshiba
Journal:  Brain Res Mol Brain Res       Date:  2000-01-10

8.  Alu-mediated inactivation of the human CMP- N-acetylneuraminic acid hydroxylase gene.

Authors:  T Hayakawa; Y Satta; P Gagneux; A Varki; N Takahata
Journal:  Proc Natl Acad Sci U S A       Date:  2001-09-18       Impact factor: 11.205

9.  Unit-length line-1 transcripts in human teratocarcinoma cells.

Authors:  J Skowronski; T G Fanning; M F Singer
Journal:  Mol Cell Biol       Date:  1988-04       Impact factor: 4.272

10.  Recombination between subtypes creates a mosaic lineage of LINE-1 that is expressed and actively retrotransposing in the mouse genome.

Authors:  J A Saxton; S L Martin
Journal:  J Mol Biol       Date:  1998-07-24       Impact factor: 5.469

View more
  150 in total

1.  Retrotransposition of marked SVA elements by human L1s in cultured cells.

Authors:  Dustin C Hancks; John L Goodier; Prabhat K Mandal; Ling E Cheung; Haig H Kazazian
Journal:  Hum Mol Genet       Date:  2011-06-02       Impact factor: 6.150

Review 2.  Active human retrotransposons: variation and disease.

Authors:  Dustin C Hancks; Haig H Kazazian
Journal:  Curr Opin Genet Dev       Date:  2012-03-08       Impact factor: 5.578

3.  Large-scale DNA editing of retrotransposons accelerates mammalian genome evolution.

Authors:  Shai Carmi; George M Church; Erez Y Levanon
Journal:  Nat Commun       Date:  2011-11-01       Impact factor: 14.919

4.  Similarities between long interspersed element-1 (LINE-1) reverse transcriptase and telomerase.

Authors:  Huira C Kopera; John B Moldovan; Tammy A Morrish; Jose Luis Garcia-Perez; John V Moran
Journal:  Proc Natl Acad Sci U S A       Date:  2011-09-22       Impact factor: 11.205

5.  Reprogramming somatic cells into iPS cells activates LINE-1 retroelement mobility.

Authors:  Silke Wissing; Martin Muñoz-Lopez; Angela Macia; Zhiyuan Yang; Mauricio Montano; William Collins; Jose Luis Garcia-Perez; John V Moran; Warner C Greene
Journal:  Hum Mol Genet       Date:  2011-10-11       Impact factor: 6.150

6.  Laboratory methods for the analysis of primate mobile elements.

Authors:  David A Ray; Kyudong Han; Jerilyn A Walker; Mark A Batzer
Journal:  Methods Mol Biol       Date:  2010

Review 7.  A LINE-1 component to human aging: do LINE elements exact a longevity cost for evolutionary advantage?

Authors:  Georges St Laurent; Neil Hammell; Timothy A McCaffrey
Journal:  Mech Ageing Dev       Date:  2010-03-25       Impact factor: 5.432

8.  L1 integration in a transgenic mouse model.

Authors:  Daria V Babushok; Eric M Ostertag; Christine E Courtney; Janice M Choi; Haig H Kazazian
Journal:  Genome Res       Date:  2005-12-19       Impact factor: 9.043

9.  LINE-like retrotransposition in Saccharomyces cerevisiae.

Authors:  Chun Dong; Russell T Poulter; Jeffrey S Han
Journal:  Genetics       Date:  2008-10-28       Impact factor: 4.562

10.  An alternative pathway for Alu retrotransposition suggests a role in DNA double-strand break repair.

Authors:  Deepa Srikanta; Shurjo K Sen; Charles T Huang; Erin M Conlin; Ryan M Rhodes; Mark A Batzer
Journal:  Genomics       Date:  2008-11-11       Impact factor: 5.736

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.